Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
5-nitroquinoline + H2O + O2
2-oxo-5-nitroquinoline + 5-aminoquinoline + 2-oxo-5-aminoquinoline
-
-
-
?
azelnidipine + H2O + O2
? + H2O2
-
-
-
?
clonazepam + H2O + O2
? + H2O2
-
-
-
?
famciclovir + H2O + O2
? + H2O2
-
-
-
?
flunitrazepam + H2O + O2
? + H2O2
-
-
-
?
flutamide + H2O + O2
? + H2O2
-
-
-
?
methotrexate + H2O + O2
7-hydroxymethotrexate + H2O2
-
-
-
?
N-(2-(dimethylamino)ethyl)acridine-4-carboxamide + H2O + O2
N-[(2-dimethylamino)ethyl] acridine-4-carboxamide-9(10H)-acridone + H2O2
-
-
-
?
N-[2-(dimethylamino)ethyl]acridine-4-carboxamide + H2O + O2
N-[(2-dimethylamino)ethyl] acridine-4-carboxamide-9(10H)-acridone + H2O2
-
-
-
?
nifedipine + H2O + O2
? + H2O2
-
-
-
?
nilutamide + H2O + O2
? + H2O2
-
-
-
?
nimesulide + H2O + O2
? + H2O2
-
-
-
?
nimetazepam + H2O + O2
? + H2O2
-
-
-
?
nimodipine + H2O + O2
? + H2O2
-
-
-
?
phenanthridine + H2O + O2
6-phenanthridone + H2O2
-
-
-
?
phthalazine + H2O + O2
1-phthalazinone + H2O2
quinazoline + H2O + O2
? + H2O2
-
-
-
?
quinoline + H2O + O2
? + H2O2
-
-
-
?
(+/-)-4-(4-cyanoanilino)-5,6-dihydro-7-hydroxy-7H-cyclopenta-[d]-pyrimidine + H2O + O2
?
-
i.e. RS-8359
-
-
?
2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide + H2O + O2
?
-
i.e. c-met inhibitor capmatinib
-
-
?
2-[(6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl)amino]ethan-1-ol + H2O + O2
? + H2O2
-
-
-
-
?
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine + H2O + O2
?
-
i.e. brimonidine
-
-
?
5-fluoropyrimidine + H2O + O2
5-fluorouracil + H2O2
-
-
-
-
?
6-benzylguanine + H2O + O2
?
-
-
-
-
?
6-chloroquinazolin-4(3H)-one + H2O + O2
6-chloroquinazoline-2,4(1H,3H)-dione + H2O2
-
-
-
-
?
6-deoxypenciclovir
penciclovir
-
is catalyzed by AOX1
-
-
?
6-deoxypenciclovir + H2O + O2
?
-
-
-
-
?
6-mercaptopurine + H2O + O2
?
-
-
-
-
?
6-methoxyquinazolin-4(3H)-one + H2O + O2
6-methoxyquinazoline-2,4(1H,3H)-dione + H2O2
-
-
-
-
?
6-methylquinazolin-4(3H)-one + H2O + O2
6-methylquinazoline-2,4(1H,3H)-dione + H2O2
-
-
-
-
?
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-(oxetan-3-yl)quinolin-3-amine + H2O + O2
? + H2O2
-
-
-
-
?
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-(oxolan-3-yl)quinolin-3-amine + H2O + O2
? + H2O2
-
-
-
-
?
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-[(oxolan-3-yl)methyl]quinolin-3-amine + H2O + O2
? + H2O2
-
-
-
-
?
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline + H2O + O2
? + H2O2
-
-
-
-
?
acetaldehyde + H2O + O2
acetic acid + H2O2
-
-
-
-
?
benzaldehyde + H2O + O2
benzoate + H2O2
-
-
-
-
?
benzaldehyde + H2O + O2
benzoic acid + H2O2
-
-
-
-
?
BIBX1382 + H2O + O2
BIBU1476 + ?
-
high hepatic clearance of 17 to 18 ml/(min * kg)
product identification by high-resolution mass spectrometry
-
?
carbazeran + H2O + O2
?
-
-
-
-
?
carbazeran + H2O + O2
carbazeran phthalazinone + ?
-
high hepatic clearance of 17 to 18 ml/(min * kg)
product identification by high-resolution mass spectrometry
-
?
imidacloprid + H2O + O2 + N-methylnicotinamide
nitroso-imidacloprid + amino-imidacloprid + H2O2 + ?
-
-
in presence of N-methylnicotinamide, ratio of amino- to nitroso-products is 26 to 50
-
?
methotrexate + H2O + O2
?
-
-
-
-
?
N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide + H2O + O2
?
-
-
-
-
?
N-[(2-dimethylamino)ethyl] acridine-4-carboxamide + H2O + O2
N-[(2-dimethylamino)ethyl] acridine-4-carboxamide-9(10H)-acridone + H2O2
-
-
-
-
?
N-[(2-dimethylamino)ethyl]acridine-4-carboxamide + H2O + O2
DACA-9(10H)-acridone + H2O2
-
N-[(2-dimethylamino)ethyl]acridine-4-carboxamide i.e. DACA, an experimental antitumor agent
-
-
?
N1-methylnicotinamide + H2O + O2
N1-methyl-2-pyridone-5-carboxamide + N1-methyl-4-pyridone-3-carboxamide + H2O2
-
-
-
-
?
O6-benzylguanine + H2O + O2
O6-benzyl-8-oxoguanine + ?
PF-4217903 + H2O + O2
?
-
-
-
-
?
PF-945863 + H2O + O2
?
-
-
-
-
?
phthalazine + O2 + H2O
1-phthalazinone + H2O2
-
-
-
-
?
pteridine + H2O + O2
?
-
-
-
-
?
quinazolin-4(3H)-one + H2O + O2
quinazoline-2,4(1H,3H)-dione + H2O2
-
-
-
-
?
quinazoline + H2O + O2
?
-
-
-
-
?
XK-469 + H2O + O2
3-oxo-XK-469 + ?
-
hepatic clearance less than 4.3 ml/(min * kg)
product identification by high-resolution mass spectrometry
-
?
XK-469 + H2O + O2
?
-
-
-
-
?
zaleplon + H2O + O2
5-oxozaleplon + ?
-
hepatic clearance less than 4.3 ml/(min * kg)
product identification by high-resolution mass spectrometry
-
?
zaleplon + H2O + O2
?
-
-
-
-
?
zebularine + H2O + O2
uridine + H2O2
-
-
major catabolic route for oral antitumor agent zebularine
-
?
zoniporide + H2O + O2
2-oxozoniporide + H2O2
-
i.e. 1-(quinolin-5-yl)-5-cyclopropyl-1H-pyrazole-4-carbonyl guanidine
-
-
?
zoniporide + H2O + O2
?
-
-
-
-
?
additional information
?
-
phthalazine + H2O + O2
1-phthalazinone + H2O2
-
-
-
?
phthalazine + H2O + O2
1-phthalazinone + H2O2
-
-
-
-
?
O6-benzylguanine + H2O + O2
O6-benzyl-8-oxoguanine + ?
-
-
-
-
?
O6-benzylguanine + H2O + O2
O6-benzyl-8-oxoguanine + ?
-
hepatic clearance of 11.2 to 12.8 ml/(min * kg)
product identification by high-resolution mass spectrometry
-
?
additional information
?
-
-
enzyme plays an important role in the biotransformation of drugs and xenobiotics, e.g. antiviral, antimalarial and antitumour compounds and nicotine
-
-
?
additional information
?
-
-
no substrate: 6-nitroquinazoinone
-
-
?
additional information
?
-
-
hepatic clearance for substrates of aldehyde oxidase i.e. BIBX1382, carbazeran, O6-benzylguanine, zaleplon, and XK-469 is investigated using cryopreserved hepatocytes
confirmation of aldehyde oxidase mediated metabolism via incubations in the presence of water containing the 18-O isotope and corresponding isotope patterns in mass spectra
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
allopurinol
does not affect the extent of the oxidation reactions of 5-nitroquinoline but instead increases the amount of reductive metabolite produced by around 60%
hydralazine
inhibits all three reactions of 5-nitroquinoline
siRNA
knock-down of AOX1 in HepG2 cells, significantly reduces ABCA1-dependent lipid efflux and enhances phagocytic uptake of microspheres similar to ABCA1 deficiency, without affecting ABCA1 mRNA and protein levels
-
5-benzylacyclouridine
-
50% inhibition at about 0.25 mM
amitriptyline
-
0.00026 mM, 50% inhibition
amlodipine
-
0.0055 mM, 50% inhibition
amodiaquine
-
0.00074 mM, 50% inhibition
clomipramine
-
0.00048 mM, 50% inhibition
cyclobenzaprine
-
0.0031 mM, 50% inhibition
epigallocatechin gallate
-
competitive
erythromycin
-
0.015 mM, 50% inhibition
felodipine
-
0.00030 mM, 50% inhibition
fenofibrate
-
in mature adipocytes, enzyme expression is reduced in presence of 50 microM fenofibrate
ketoconazole
-
0.0035 mM, 50% inhibition
loperamide
-
0.010 mM, 50% inhibition
loratidine
-
0.00049 mM, 50% inhibition
loxapine
-
0.0023 mM, 50% inhibition
maprotiline
-
0.0014 mM, 50% inhibition
metoclopramide
-
0.031 mM, 50% inhibition
norclomipramine
-
0.00060 mM, 50% inhibition
nortriptyline
-
0.00085 mM, 50% inhibition
olanzapine
-
0.0060 mM, 50% inhibition
ondansetron
-
0.0021 mM, 50% inhibition
palmitic acid
-
enzyme expression is reduced in 3T3-L1 cells differentiated in presence of 400 microM palmitic acid
perphenazine
-
0.00003 mM, 50% inhibition
promazine
-
0.0016 mM, 50% inhibition
Promethazine
-
0.00051 mM, 50% inhibition
propafenone
-
0.0025 mM, 50% inhibition
quercetin
-
mixed type inhibition
Quinacrine
-
0.0033 mM, 50% inhibition
salmeterol
-
0.0099 mM, 50% inhibition
tacrine
-
0.0050 mM, 50% inhibition
thioridazine
-
0.00016 mM, 50% inhibition
Trifluperazine
-
0.00024 mM, 50% inhibition
verapamil
-
0.0035 mM, 50% inhibition
additional information
-
addition of 100 microM allopurinol has no significant effect on enzyme activity
-
chlorpromazine
-
-
chlorpromazine
-
0.00057 mM, 50% inhibition
clozapine
-
-
clozapine
-
0.0044 mM, 50% inhibition
domperidone
-
-
domperidone
-
0.0030 mM, 50% inhibition
estradiol
-
-
estradiol
-
0.00029 mM, 50% inhibition
estradiol
-
uncompetitive, with no inhibition towards the tested CYP450 enzymes
ethinyl estradiol
-
-
ethinyl estradiol
-
0.00057 mM, 50% inhibition
hydralazine
-
100 microM reduces enzyme activity by as much as 96%
hydralazine
-
upon coincubation of BIBX1382, carbazeran, and O6-benzylguanine with 50 microM hydralazine, metabolic clearance is substantially attenuated
menadione
-
-
menadione
-
0.00020 mM, 50% inhibition
menadione
-
specific inhibitor of aldehyde oxidase
quetiapine
-
0.0014 mM, 50% inhibition
quetiapine
-
additionally shows inhibition towards the major CYP450 enzymes tested
raloxifene
-
-
raloxifene
-
0.000003 mM, 50% inhibition
raloxifene
-
50% inhibition at about 8 nM
raloxifene
-
specific inhibitor of aldehyde oxidase, complete inhibition at 0.01 mM
raloxifene
-
additionally acts as non-specific inhibitor of all major tested CYP450 enzymes
tamoxifen
-
-
tamoxifen
-
0.0022 mM, 50% inhibition
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Amyotrophic Lateral Sclerosis
Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Inhibition of vertebrate aldehyde oxidase as a therapeutic treatment for cancer, obesity, aging and amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Lou Gehrig's disease linked to aldehyde oxidase.
Amyotrophic Lateral Sclerosis
Selective localization of mouse aldehyde oxidase mRNA in the choroid plexus and motor neurons.
Carcinogenesis
DNA cleavage during ethanol metabolism: role of superoxide radicals and catalytic iron.
Carcinoma
Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity.
Carcinoma, Ehrlich Tumor
Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro.
Carcinoma, Hepatocellular
Identification of aldehyde oxidase 1 and aldehyde oxidase homologue 1 as dioxin-inducible genes.
Carcinoma, Renal Cell
Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity.
Colorectal Neoplasms
Aldehyde oxidase 1 promoted the occurrence and development of colorectal cancer by up-regulation of expression of CD133.
Diabetes Mellitus, Type 2
[Chronic nicotinamide overload and type 2 diabetes.]
Drug-Related Side Effects and Adverse Reactions
Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy.
Fatty Liver
Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition.
Fatty Liver
Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase.
Genetic Diseases, Inborn
Rescue of lethal molybdenum cofactor deficiency by a biosynthetic precursor from Escherichia coli.
Herpes Simplex
6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.
Herpes Simplex
Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.
Infections
Aldehyde oxidase (AO) in the root nodules of Lupinus albus and Medicago truncatula: identification of AO in meristematic and infection zones.
Infections
The involvement of ROS producing aldehyde oxidase in plant response to Tombusvirus infection.
Influenza, Human
Dietary Flavonoid Aglycones and Their Glycosides: Which Show Better Biological Significance?
Influenza, Human
Flavonoid glycosylation and biological benefits.
Kidney Diseases
Metabolism and disposition kinetics of nicotine.
Leukemia
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins.
Liver Cirrhosis, Alcoholic
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study.
Liver Diseases
[Chronic nicotinamide overload and type 2 diabetes.]
Lung Injury
Role of xanthine oxidase and neutrophils in ischemia-reperfusion injury in rabbit lung.
Motor Neuron Disease
Selective localization of mouse aldehyde oxidase mRNA in the choroid plexus and motor neurons.
Neoplasms
Alteration in Gene Pair Correlations in Tryptophan Metabolism as a Hallmark in Cancer Diagnosis.
Neoplasms
An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Neoplasms
Compound K, a ginsenoside metabolite, plays an antiinflammatory role in macrophages by targeting the AKT1-mediated signaling pathway.
Neoplasms
Cyclophosphamide potentiation and aldehyde oxidase inhibition by phosphorylated aldehydes and acetals.
Neoplasms
Expression and prognostic relevance of long noncoding RNAs CRNDE and AOX2P in adult acute myeloid leukemia.
Neoplasms
Expression of AOX1 Predicts Prognosis of Clear Cell Renal Cell Carcinoma.
Neoplasms
Inhibition of vertebrate aldehyde oxidase as a therapeutic treatment for cancer, obesity, aging and amyotrophic lateral sclerosis.
Neoplasms
Metabolism of methotrexate and gamma-tert-butyl methotrexate by human leukemic cells in culture and by hepatic aldehyde oxidase in vitro.
Neoplasms
Metabolism of retinol and retinoic acid in N-methyl-N-nitrosourea-induced mammary carcinomas in rats.
Neoplasms
Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Neoplasms
Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro.
Nervous System Diseases
Prenatal diagnosis and carrier detection for molybdenum cofactor deficiency type A in northern Israel using polymorphic DNA markers.
Nervous System Diseases
The peak height ratio of S-sulfonated transthyretin and other oxidized isoforms as a marker for molybdenum cofactor deficiency, measured by electrospray ionization mass spectrometry.
Obesity
Inhibition of vertebrate aldehyde oxidase as a therapeutic treatment for cancer, obesity, aging and amyotrophic lateral sclerosis.
Ovarian Neoplasms
Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.
Stillbirth
Evidence that fetal death is associated with placental aging.
Thyroid Neoplasms
Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity.
Tuberculosis
Biotransformation and bioactivation reactions - 2015 literature highlights.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.073 - 0.912
5-nitroquinoline
-
0.0067
clonazepam
liver cytosol, pH 7.4, 37°C
-
0.046
flunitrazepam
liver cytosol, pH 7.4, 37°C
0.053
flutamide
liver cytosol, pH 7.4, 37°C
2.792
methotrexate
pH 7.5, 37°C
0.0383
nilutamide
liver cytosol, pH 7.4, 37°C
-
0.2014
nimesulide
liver cytosol, pH 7.4, 37°C
0.0185
nimetazepam
liver cytosol, pH 7.4, 37°C
-
0.0026
2-[(6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl)amino]ethan-1-ol
-
liver cytosol, pH not specified in the publication, temperature not specified in the publication
-
0.027
6-chloroquinazolin-4(3H)-one
-
pH 7.4, 22°C
0.293
6-methoxyquinazolin-4(3H)-one
-
pH 7.4, 22°C
0.142
6-methylquinazolin-4(3H)-one
-
pH 7.4, 22°C
0.022
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-(oxetan-3-yl)quinolin-3-amine
-
liver cytosol, pH not specified in the publication, temperature not specified in the publication
-
0.0086
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-(oxolan-3-yl)quinolin-3-amine
-
liver cytosol, pH not specified in the publication, temperature not specified in the publication
-
0.063
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-N-[(oxolan-3-yl)methyl]quinolin-3-amine
-
liver cytosol, pH not specified in the publication, temperature not specified in the publication
-
0.084
6-[[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline
-
liver cytosol, pH not specified in the publication, temperature not specified in the publication
-
0.004 - 0.015
benzaldehyde
-
-
0.008 - 0.014
N-[(2-dimethylamino)ethyl] acridine-4-carboxamide
-
-
0.0063
N-[(2-dimethylamino)ethyl]acridine-4-carboxamide
-
pH 7.4 and 37°C
0.12
O6-benzylguanine
-
pH 7.4, 37°C
0.399
quinazolin-4(3H)-one
-
pH 7.4, 22°C
0.0073 - 0.0084
zebularine
0.0034
zoniporide
-
in 25 mM phosphate buffer at 37°C, pH not specified in the publication
0.073
5-nitroquinoline
metabolite 2-oxo-5-aminoquinoline, pH 7.4, 37°C
-
0.1
5-nitroquinoline
metabolite 5-aminoquinoline, presence of N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, pH 7.4, 37°C
-
0.912
5-nitroquinoline
metabolite 2-oxo-5-nitroquinoline, pH 7.4, 37°C
-
0.912
5-nitroquinoline
metabolite 2-oxo-5-nitroquinoline, presence of N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, pH 7.4, 37°C
-
0.0073
zebularine
-
male, pH 7.5, 37°C
0.0084
zebularine
-
female, pH 7.5, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Al-Salmy, H.S.
Individual variation in hepatic aldehyde oxidase activity
IUBMB Life
51
249-253
2001
Homo sapiens
brenda
Obach, R.S.; Huynh, P.; Allen, M.C.; Beedham, C.
Human liver aldehyde oxidase: inhibition by 239 drugs
J. Clin. Pharmacol.
44
7-19
2004
Homo sapiens
brenda
Klecker, R.W.; Cysyk, R.L.; Collins, J.M.
Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors
Bioorg. Med. Chem.
14
62-66
2006
Canis lupus familiaris, Homo sapiens, Macaca fascicularis, Mus musculus, Mus musculus CD-1, Rattus norvegicus
brenda
Dick, R.A.; Kanne, D.B.; Casida, J.E.
Identification of aldehyde oxidase as the neonicotinoid nitroreductase
Chem. Res. Toxicol.
18
317-323
2005
Gallus gallus, Homo sapiens, Macaca fascicularis, Oryctolagus cuniculus, Rattus norvegicus
brenda
Yamaguchi, Y.; Matsumura, T.; Ichida, K.; Okamoto, K.; Nishino, T.
Human Xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate
J. Biochem.
141
513-524
2007
Homo sapiens
brenda
Garattini, E.; Fratelli, M.; Terao, M.
Mammalian aldehyde oxidases: genetics, evolution and biochemistry
Cell. Mol. Life Sci.
65
1019-1048
2008
Arabidopsis thaliana (Q7G191), Arabidopsis thaliana (Q7G192), Arabidopsis thaliana (Q7G193), Bos taurus (P48034), Caenorhabditis elegans (O61198), Caenorhabditis elegans (Q960A1), Canis lupus familiaris (Q2QB47), Canis lupus familiaris (Q2QB48), Danio rerio, Drosophila melanogaster, Drosophila melanogaster (Q9VF53), Equus caballus, Gallus gallus (Q2QB49), Gallus gallus (Q2QB50), Homo sapiens, Macaca fascicularis (Q5FB27), Macaca mulatta, Mamestra brassicae (Q4VGM3), Monodelphis domestica, Mus musculus, Mus musculus (O54754), Mus musculus (Q5SGK3), Mus musculus (Q6V956), Mus musculus (Q8VJ15), no activity in Aspergillus nidulans, Oryctolagus cuniculus (P80456), Pan troglodytes, Pongo pygmaeus, Rattus norvegicus, Rattus norvegicus (Q5QE78), Rattus norvegicus (Q5QE79), Rattus norvegicus (Q5QE80), Rattus norvegicus (Q9Z0U5), Solanum lycopersicum (Q9FV23), Solanum lycopersicum (Q9FV24), Solanum lycopersicum (Q9FV25), Takifugu rubripes, Tetraodon nigroviridis, Xenopus laevis (Q6GMC5), Zea mays (O23887), Zea mays (O23888)
brenda
Tayama, Y.; Miyake, K.; Sugihara, K.; Kitamura, S.; Kobayashi, M.; Morita, S.; Ohta, S.; Kihira, K.
Developmental changes of aldehyde oxidase activity in young Japanese children
Clin. Pharmacol. Ther.
81
567-572
2007
Homo sapiens
brenda
Graessler, J.; Fischer, S.
The dual substrate specificity of aldehyde oxidase 1 for retinal and acetaldehyde and its role in ABCA1 mediated efflux
Horm. Metab. Res.
39
775-776
2007
Homo sapiens, Rattus norvegicus, Bos taurus (P48034), Oryctolagus cuniculus (P80456), Gallus gallus (Q2QB50)
brenda
Sigruener, A.; Buechler, C.; Orso, E.; Hartmann, A.; Wild, P.J.; Terracciano, L.; Roncalli, M.; Bornstein, S.R.; Schmitz, G.
Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes
Horm. Metab. Res.
39
781-789
2007
Homo sapiens (Q06278), Homo sapiens
brenda
Alfaro, J.F.; Joswig-Jones, C.A.; Ouyang, W.; Nichols, J.; Crouch, G.J.; Jones, J.P.
Purification and mechanism of human aldehyde oxidase (Aox1) expressed in E. coli
Drug Metab. Dispos.
37
2393-2398
2009
Homo sapiens
brenda
Weigert, J.; Neumeier, M.; Bauer, S.; Mages, W.; Schnitzbauer, A.A.; Obed, A.; Groeschl, B.; Hartmann, A.; Schaeffler, A.; Aslanidis, C.; Schoelmerich, J.; Buechler, C.
Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release
FEBS Lett.
582
2965-2972
2008
Homo sapiens, Mus musculus
brenda
Zientek, M.; Jiang, Y.; Youdim, K.; Obach, R.S.
In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase
Drug Metab. Dispos.
38
1322-1327
2010
Homo sapiens
brenda
Dalvie, D.; Zhang, C.; Chen, W.; Smolarek, T.; Obach, R.S.; Loi, C.M.
Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences
Drug Metab. Dispos.
38
641-654
2010
Homo sapiens
brenda
Hutzler, J.M.; Yang, Y.S.; Albaugh, D.; Fullenwider, C.L.; Schmenk, J.; Fisher, M.B.
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes
Drug Metab. Dispos.
40
267-275
2012
Homo sapiens
brenda
Barr, J.T.; Jones, J.P.
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase
Drug Metab. Dispos.
41
24-29
2013
Homo sapiens
brenda
Choughule, K.V.; Joswig-Jones, C.A.; Jones, J.P.
Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase
Biochem. Pharmacol.
96
288-295
2015
Oryctolagus cuniculus (O54754), Oryctolagus cuniculus, Homo sapiens (Q06278), Homo sapiens
brenda
Barr, J.T.; Jones, J.P.; Oberlies, N.H.; Paine, M.F.
Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance
Drug Metab. Dispos.
43
34-41
2015
Homo sapiens
brenda
Xu, Y.; Li, L.; Wang, Y.; Xing, J.; Zhou, L.; Zhong, D.; Luo, X.; Jiang, H.; Chen, K.; Zheng, M.; Deng, P.; Chen, X.
Aldehyde oxidase mediated metabolism in drug-like molecules: a combined computational and experimental study
J. Med. Chem.
60
2973-2982
2017
Homo sapiens
brenda
Nirogi, R.; Kandikere, V.; Palacharla, R.C.; Bhyrapuneni, G.; Kanamarlapudi, V.B.; Ponnamaneni, R.K.; Manoharan, A.K.
Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions
Xenobiotica
44
197-204
2014
Homo sapiens
brenda
Ferreira, P.; Cerqueira, N.; Fernandes, P.; Romao, M.; Ramos, M.
Catalytic Mechanism of human aldehyde oxidase
ACS Catal.
10
9276-9286
2020
Homo sapiens (Q06278)
-
brenda
Montefiori, M.; Jorgensen, F.S.; Olsen, L.
Aldehyde oxidase reaction mechanism and prediction of site of metabolism
ACS Omega
2
4237-4244
2017
Homo sapiens (Q06278)
brenda
Ogiso, T.; Fukami, T.; Mishiro, K.; Konishi, K.; Jones, J.P.; Nakajima, M.
Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs
Arch. Biochem. Biophys.
659
85-92
2018
Homo sapiens (Q06278), Homo sapiens
brenda
Paragas, E.M.; Humphreys, S.C.; Min, J.; Joswig-Jones, C.A.; Jones, J.P.
The two faces of aldehyde oxidase Oxidative and reductive transformations of 5-nitroquinoline
Biochem. Pharmacol.
145
210-217
2017
Homo sapiens (Q06278), Homo sapiens
brenda
Zhang, J.W.; Xiao, W.; Gao, Z.T.; Yu, Z.T.; Zhang, J.Y.J.
Metabolism of c-Met kinase inhibitors containing quinoline by aldehyde oxidase, electron donating, and steric hindrance effect
Drug Metab. Dispos.
46
1847-1855
2018
Macaca fascicularis, Homo sapiens, Mus musculus, Rattus norvegicus
brenda